FDA approved ustekinumab for patients aged two years and older with moderately to severely active Crohn’s disease.
What this means
Stelara is an injectable antibody drug that blocks two immune system proteins, IL-12 and IL-23, which play a role in inflammation. Today FDA approved Stelara for children as young as two years old with moderate to severe Crohn’s disease. This decision gives younger patients access to a treatment option that was previously only available for adults and older teens.
